Farukh Bashir, Quratulain, Khawar Abbas Choudhery, Mujtaba Hassan, Imran Yasin.
Role of Cabergoline in High Risk for Ovarian Hyper Stimulation Syndrome (OHSS) Prophylaxis Undergoing IVF/ ICSI Treatment Cycles.
Pak J Med Health Sci Jan ;13(1):71-3.

Background: Ovarian hyper stimulation syndrome (OHSS) is defined as a complication related to stimulation of ovaries and is considered a life threatening condition of unknown etiology. Aim: To see the effect of cabergoline (dopamine agonist) as preventive therapy in ovarian hyper stimulation syndrome (OHSS) during IVF/ICSI treatment cycles. Study design: Prospective cohort study Study period: 22 months period. From August 2015 to June 2017 Methods: Fifty females who were having risk factors of developing OHSS and were undergoing IVF/ICSI treatment cycle, these patients were given 0.5 mg of cabergoline (Dostinex) from the day of ovum pickup for total of eight day. Married couple whose spouses have not conceived after one year of unprotected sex, pcos, age less than 30 year, low BMI, No of eggs picked up for ICSI = 20 eggs or more. Ovarian size from 10-15 cm+/- ascites. E2 level on day of ovum pick up >3000pg/ml smoking, obesity, diabetes mellitus, age more than 30 years. Estrogen more than 5000pg/ml. Data analysis: Statistical analysis was carried out using SPSS version 19.0, Student’s t test was used to detect significance of cabergoline use in sub fertile females. Results: 50 sub fertile women were included and assessed, there was significant lowering of OHSS with the use of cabergoline the dopamine agonist reduced the occurrence of the severe and moderate OHSS by 50%. But more significant reduction was seen in moderate OHSS, as fewer cases of severe OHSS was seen. No difference in live birth rate and ongoing pregnancy rate was observed in patients who were taking cabergoline. No significant side effects of cabergoline have observed during study period. Conclusion: Use of dopamine agonist cabergoline at doses (0.5 mg) to prevent OHSS in females at high risk is very effective in reducing chance of OHSS and in IVF/ICSI treatment cycles.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com